A reference in NASH models, validated with benchmarks, to rapidly evaluate your compounds targeting NASH

Key benefits
- Evaluate your drug in a classical NASH model, validated in-house by Physiogenex with reference drugs: get a deep evaluation (biochemistry, histology and NAS score) of your compounds targeting NASH in less than 3 months.

ANIMAL MODEL
- Strain: C57BL/6J mouse
- Diet: Methionine Choline Deficient diet
- Study duration: 4 to 8 weeks
- Reference compounds: pioglitazone (PPARγ agonist), WAY-362450 and obeticholic acid (FXR agonists)

EFFECTS OF MCD DIET
MCD DIET INCREASES LIVER ENZYMES AND PROMOTES NASH

EFFECTS OF FXR AGONIST WAY-362450
FXR agonist WAY-362450 improves NAS scoring by reducing inflammation and fibrosis, but not steatosis

EFFECTS OF FXR AGONIST OBETICHOLIC ACID
Obeticholic acid improves NAS scoring by reducing liver steatosis and ballooning

EFFECTS OF PIOGLITAZONE
Pioglitazone improves NAS scoring with a strong reduction in liver triglycerides

***p<0.01 vs. chow diet
*p<0.05, **p<0.01 and ***p<0.01 vs. respective vehicle

PHYSIogenex SAS - Prologue Biotech – 516 Rue Pierre et Marie Curie – 31870 Labège Cedex – France Phone: +33 561 287 040 - business@physiogenex.com www.physiogenex.com